(Q53043343)

English

Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission.

scientific article published on 20 May 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

Noel Jean Milpied

object named as

N Milpied

6

0 references

author name string

J Versluis

1

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

M Labopin

2

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

D Niederwieser

3

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

G Socie

4

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

R F Schlenk

5

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

A Nagler

7

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

D Blaise

8

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

V Rocha

9

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

J J Cornelissen

10

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

M Mohty

11

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

publication date

20 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

29

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

1

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

51-57

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

https://scigraph.springernature.com/pub.10.1038/leu.2014.164

0 references

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Acute myeloid leukemia in the real world: why population-based registries are needed

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Hematopoietic SCT in Europe: data and trends in 2011.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients underg

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Regression modeling of competing crude failure probabilities

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

How I assess comorbidities before hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

A Proportional Hazards Model for the Subdistribution of a Competing Risk

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Regression modelling strategies for improved prognostic prediction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Internal and external validation of predictive models: a simulation study of bias and precision in small samples

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell T

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.164

21 January 2018

CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality

1 reference

https://pubmed.ncbi.nlm.nih.gov/24913728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantat

1 reference

https://pubmed.ncbi.nlm.nih.gov/24913728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A risk score for mortality after allogeneic hematopoietic cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24913728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

https://pubmed.ncbi.nlm.nih.gov/24913728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT

1 reference

https://pubmed.ncbi.nlm.nih.gov/24913728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A modified comorbidity index for hematopoietic cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24913728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24913728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/24913728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2014.164

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/24913728

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53043343&oldid=1423264328"